OncoMatch/Lung Cancer — Non-Small Cell (NSCLC)/NTRK1

Lung Cancer — Non-Small Cell (NSCLC)NTRK1 Clinical Trials

17 recruiting trials·Updated daily from ClinicalTrials.gov

NTRK1 fusions are rare drivers in NSCLC (<1%) but respond to tumor-agnostic NTRK inhibitors larotrectinib and entrectinib, both FDA-approved regardless of cancer type. Resistance emerges via acquired kinase domain mutations. Trials investigate next-generation NTRK inhibitors designed to overcome on-target resistance.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting NTRK1 Lung Cancer — Non-Small Cell (NSCLC) trials

Ranked by phase and US site count.

See all trials matched to your profile →

Phase 3

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Shouyao Holdings (Beijing) Co. LTD

Phase 3

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Sinocelltech Ltd.

Phase 3

D-BACE in Combination With Chemotherapy and Carelizumab for Resectable II-IIIA or Potentially Resectable T3-4N2 Stage IIIB NSCLC

Guangdong Provincial People's Hospital

Phase 2267 US sites

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

SWOG Cancer Research Network

Phase 238 US sites

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Genentech, Inc.

Phase 27 US sites

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Memorial Sloan Kettering Cancer Center

Additional trials

More NTRK1 Lung Cancer — Non-Small Cell (NSCLC) trials

Phase 2

NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaPhase 26 US sites NCT07250477Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung CancerPhase 21 US site NCT07111520A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)Phase 1/Phase 21 US site NCT05589818Pembrolizumab for Advanced NSCLC and PS 2-3Phase 21 US site NCT06364917DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLCPhase 21 US site NCT03556228VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPhase 1/Phase 214 US sites

5 international trials (no US sites)

NCT06563999Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 NCT04996121A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid TumorsPhase 1/Phase 2 NCT06929936Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLCPhase 2 NCT06440954Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal MetastasesPhase 2 NCT06734182Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung CancerPhase 2

Related therapies

FDA-approved therapies for NTRK1 Lung Cancer — Non-Small Cell (NSCLC)

Approved agents for this molecular target. Indication labels specify the approved patient population — some approvals apply to specific variants only.

EntrectinibROS1 and TRK inhibitorNTRK fusion-positive solid tumors, tumor-agnostic (FDA Aug 2019)RepotrectinibNext-generation ROS1/TRK inhibitorNTRK fusion-positive solid tumors, tumor-agnostic (FDA Jun 2024, accelerated)

Other Lung Cancer — Non-Small Cell (NSCLC) biomarkers

Browse other molecular targets with active Lung Cancer — Non-Small Cell (NSCLC) trials.

EGFR ALK ROS1 PD-L1 (CD274)KRAS MET HER2 (ERBB2)BRAF RET NTRK2 NTRK3

← All Lung Cancer — Non-Small Cell (NSCLC) clinical trials